AgingResearch.NewsJoin free

RGT-075

Intervention

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab
  • Human trial1

Outcomes

3

Diastolic blood pressure

downin humans1

1 study

  1. RGT-075 decreases diastolic blood pressure in humans (-4.9 mmHg (placebo adjusted)).

    “significant and clinical meaningful reduction of systolic (-10.8 mmHg (placebo adjusted), p = 0.0022) and diastolic (-4.9 mmHg (placebo adjusted), p = 0.0371) blood pressure was observed.”

    Human trialadults with obesity or overweight125 mg QD12 weeksn = 50

    First Report on the Small Molecule Oral GLP-1 Receptor Agonist RGT-075 in Obesity—A Randomized, Placebo-Controlled Phase 2a Proof-of-Concept Twelve-Week Study

    ADA Scientific Sessions 2025 abstract13 Jun 2025

More on Diastolic blood pressure

Systolic blood pressure

downin humans1

1 study

  1. RGT-075 decreases systolic blood pressure in humans (-10.8 mmHg (placebo adjusted)).

    “significant and clinical meaningful reduction of systolic (-10.8 mmHg (placebo adjusted), p = 0.0022) and diastolic (-4.9 mmHg (placebo adjusted), p = 0.0371) blood pressure was observed.”

    Human trialadults with obesity or overweight125 mg QD12 weeksn = 50

    First Report on the Small Molecule Oral GLP-1 Receptor Agonist RGT-075 in Obesity—A Randomized, Placebo-Controlled Phase 2a Proof-of-Concept Twelve-Week Study

    ADA Scientific Sessions 2025 abstract13 Jun 2025

More on Systolic blood pressure

Body weight

downin humans1

1 study

  1. RGT-075 decreases body weight in humans (-5.4% vs -0.45%).

    “At week 12, the LS mean percentage change in body weight was -5.4% with RGT-075 (no plateau) compared to -0.45% with placebo (p < 0.0001).”

    Human trialadults with obesity or overweight125 mg QD12 weeksn = 50

    First Report on the Small Molecule Oral GLP-1 Receptor Agonist RGT-075 in Obesity—A Randomized, Placebo-Controlled Phase 2a Proof-of-Concept Twelve-Week Study

    ADA Scientific Sessions 2025 abstract13 Jun 2025

Latest

Related